Bernardo Sousa-Pinto

Dr. Bernardo Sousa-Pinto


Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 June 2017 in Molecular Nutrition & Food Research
Verified
Journal Article
Closed access
PDF file
José Carlos RibeiroJosé Carlos Ribeiro
José Carlos Ribeiro
Luís Miguel CunhaLuís Miguel Cunha
Luís Miguel Cunha
BSBernardo Sousa-Pinto
Bernardo Sousa-Pinto
JFJoao A. da Fonseca
Joao A. da Fonseca

10 April 2023 in Allergy
Verified
Journal Article
Open access
Jean BousquetJean Bousquet
Jean Bousquet
EME. Melén
E. Melén
THT. Haahtela
T. Haahtela
GKG. H. Koppelman
G. H. Koppelman
ATAlkis Togias
Alkis Togias
Josep M. BoquéJosep M. Boqué
Josep M. Boqué
Asthma, rhinitis, and atopic dermatitis (AD) are interrelated clinical phenotypes that partly overlap in the human interactome. The concept of “one‐airway‐one‐disease,” coined over 20 years ago, is a simplistic approach of the links between upper‐ and lower‐airway allergic diseases. With new data, it is time to reassess the concept. This article reviews (i) the clinical observations that led to Allergic Rhinitis and its Impact on Asthma (ARIA), (ii) new insights into polysensitization and multimorbidity, (iii) advances in mHealth for novel phenotype definitions, (iv) confirmation in canonical epidemiologic studies, (v) genomic findings, (vi) treatment approaches, and (vii) novel concepts on the onset of rhinitis and multimorbidity. One recent concept, bringing together upper‐ and lower‐airway allergic diseases with skin, gut, and neuropsychiatric multimorbidities, is the “Epithelial Barrier Hypothesis.” This review determined that the “one‐airway‐one‐disease” concept does not always hold true and that several phenotypes of disease can be defined. These phenotypes include an extreme “allergic” (asthma) phenotype combining asthma, rhinitis, and conjunctivitis. Rhinitis alone and rhinitis and asthma multimorbidity represent two distinct diseases with the following differences: (i) genomic and transcriptomic background (Toll‐Like Receptors and IL‐17 for rhinitis alone as a local disease; IL‐33 and IL‐5 for allergic and non‐allergic multimorbidity as a systemic disease), (ii) allergen sensitization patterns (mono‐ or pauci‐sensitization versus polysensitization), (iii) severity of symptoms, and (iv) treatment response. In conclusion, rhinitis alone (local disease) and rhinitis with asthma multimorbidity (systemic disease) should be considered as two distinct diseases, possibly modulated by the microbiome, and may be a model for understanding the epidemics of chronic and autoimmune diseases.

1 October 2017 in Annals of Allergy, Asthma & Immunology
Verified
Journal Article
Closed access
BSBernardo Sousa-Pinto
Bernardo Sousa-Pinto
JFJoao A. da Fonseca
Joao A. da Fonseca
EGEva Rebelo Gomes
Eva Rebelo Gomes

10 August 2020 in Journal of Medical Internet Research
Verified
Journal Article
Open access
BSBernardo Sousa-Pinto
Bernardo Sousa-Pinto
AAAram Anto
Aram Anto
WCWienia Czarlewski
Wienia Czarlewski
Josep M. BoquéJosep M. Boqué
Josep M. Boqué
JFJoao A. da Fonseca
Joao A. da Fonseca
Jean BousquetJean Bousquet
Jean Bousquet
Background: The influence of media coverage on web-based searches may hinder the role of Google Trends (GT) in monitoring coronavirus disease (COVID-19). Objective: The aim of this study was to assess whether COVID-19–related GT data, particularly those related to ageusia and anosmia, were primarily related to media coverage or to epidemic trends. Methods: We retrieved GT query data for searches on coronavirus, cough, anosmia, and ageusia and plotted them over a period of 5 years. In addition, we analyzed the trends of those queries for 17 countries throughout the year 2020 with a particular focus on the rises and peaks of the searches. For anosmia and ageusia, we assessed whether the respective GT data correlated with COVID-19 cases and deaths both throughout 2020 and specifically before March 16, 2020 (ie, the date when the media started reporting that these symptoms can be associated with COVID-19). Results: Over the last five years, peaks for coronavirus searches in GT were only observed during the winter of 2020. Rises and peaks in coronavirus searches appeared at similar times in the 17 different assessed countries irrespective of their epidemic situations. In 15 of these countries, rises in anosmia and ageusia searches occurred in the same week or 1 week after they were identified in the media as symptoms of COVID-19. When data prior to March 16, 2020 were analyzed, anosmia and ageusia GT data were found to have variable correlations with COVID-19 cases and deaths in the different countries. Conclusions: Our results indicate that COVID-19–related GT data are more closely related to media coverage than to epidemic trends.

21 May 2020 in Journal of Allergy and Clinical Immunology
Verified
Journal Article
Closed access
BSBernardo Sousa-Pinto
Bernardo Sousa-Pinto
ITIsabel Tarrio
Isabel Tarrio
KBKimberly G. Blumenthal
Kimberly G. Blumenthal
LALuís Araújo
Luís Araújo
LALuís Azevedo
Luís Azevedo
JFJoão Almeida Fonseca
João Almeida Fonseca

28 February 2020 in Clinical Infectious Diseases
Verified
Journal Article
Closed access
PDF file
BSBernardo Sousa-Pinto
Bernardo Sousa-Pinto
KBKimberly G Blumenthal
Kimberly G Blumenthal
EMEric Macy
Eric Macy
APAna Margarida Pereira
Ana Margarida Pereira
LALuís Azevedo
Luís Azevedo
JFJoao A. da Fonseca
Joao A. da Fonseca
Background: Having a penicillin allergy label is associated with the use of less appropriate and more expensive antibiotics and increased healthcare utilization. Penicillin allergy testing results in delabeling most allergy claimants and may be cost-saving. This study aimed to project whether penicillin allergy testing in patients reporting a penicillin allergy is cost-saving.Methods: In this economic evaluation study, we built decision models to project the economic impact of 2 strategies for a patient with a penicillin allergy label: (1) perform diagnostic testing (drug challenges, with or without skin tests); and (2) do not perform diagnostic testing. The health service perspective was adopted, considering costs with penicillin allergy tests, and with hospital bed-days/outpatient visits, antibiotic use, and diagnostic testing. Twenty-four base case decision models were built, accounting for differences in the diagnostic workup, setting (inpatient vs outpatient) and geographic region. Uncertainty was explored via probabilistic sensitivity analyses.Results: Penicillin allergy testing was cost-saving in all decision models built. For models assessing the performance of both skin tests and drug challenges, allergy testing resulted in average savings (in United States [US] dollars) of $657 for inpatients (US: $1444; Europe: $489) and $2746 for outpatients (US: $256; Europe: $6045). 75% of simulations obtained through probabilistic sensitivity analysis identified testing as the less costly option.Conclusions: Penicillin allergy testing was projected to be cost-saving across different scenarios. These results are devised to inform guidelines, supporting the adoption of policies promoting widespread testing of patients with a penicillin allergy label.